Advancing Medicinal Chemistry Through FMO: Sygnature's Platform.

Alexander Heifetz, Girinath G Pillai, Anna Cavalleri, Maryamdokht Taimoory, Louise Birch, Colin Sambrook Smith

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexander HeifetzSygnature Discovery, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK. alexander.heifetz@sygnaturediscovery.com.

Girinath G PillaiSygnature Discovery, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK.

Anna CavalleriSygnature Discovery, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK.

Maryamdokht TaimoorySygnature Discovery, 201-2350 Cohen Saint-Laurent, H4R 2N6, , Montréal, QC, Canada.

Louise BirchSygnature Discovery, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK.

Colin Sambrook SmithSygnature Discovery, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The FMO Sygnature Platform (FMO-SP) transforms the fragment molecular orbital method (FMO) into a practical framework for drug discovery by combining quantum-level accuracy with workflow automation and intuitive visualization. FMO-SP quantifies residue-level stabilizing and destabilizing interactions, including solvation and polarisation effects, that are often missed by classical force fields. Three showcases illustrate its broad applicability. In kinase design (p38α MAPK), integration with nonequilibrium simulation/molecular dynamics (NES/MD) linked energetic magnitude with dynamic persistence, distinguishing consistent hot spots from transient interactions and informing strategies for potency. In safety pharmacology, application to the hERG potassium channel revealed how burial of a ligand's basic center within the channel's negative electrostatic field drives blockade, highlighting pK

Indexed as

Chemistry, PharmaceuticalDrug DiscoveryDrug DesignHumansLigandsMolecular Dynamics SimulationLigandsAI-driven drug designAntibody–drug conjugates (ADC)AutomationDesolvationDocking posesElectrostatic complementarityFMO-SPFragment molecular orbital (FMO)hERGHigh-throughput screeningHomology modellingLead optimizationMolecular dynamics (MD)Molecular gluesPair interaction energy decomposition analysis (PIEDA)Pair interaction energy (PIE)PolarizationPROTACsProtein–ligand interactionsProtein–protein interactions (PPIs)Quantum mechanicsStructure-based drug design (SBDD)

Identifiers

PMID42604897

DOI10.1016/j.celrep.2021.109374

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.